Last updated: July 12, 2023
Sponsor: Fuling Zhou
Overall Status: Active - Recruiting
Phase
1
Condition
Multiple Myeloma
Lymphoproliferative Disorders
Bone Diseases
Treatment
DFPP combined with chemotherapy
Clinical Study ID
NCT04836871
01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology
- Patients with stable condition after conventional treatment
- Patients with renal insufficiency or abnormal M protein
- Patients over 18 years of age
- Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/akaalanine aminotransferase (ALT) is less than 2 times the upper limit of normal
- Normal heart function
- Physical condition score 0-2 level (ECOG score)
- Obtain an informed consent form signed by the patient or family member
Exclusion
Exclusion Criteria:
- Allergies or obvious contraindications to any of the drugs involved in the plan
- Severe heart disease, including myocardial infarction and cardiac insufficiency.
- Suffering from other organ malignancies
- Active tuberculosis patients and HIV-positive patients
- At the same time suffering from other blood system diseases
- Pregnant or lactating women
- Able to understand or follow the research plan
- Past history of intolerance or allergy to similar drugs
- Patients under 18 years of age
- Participating in other clinical researchers at the same time
- There are any other circumstances that hinder the progress of the research
Study Design
Total Participants: 20
Treatment Group(s): 1
Primary Treatment: DFPP combined with chemotherapy
Phase: 1
Study Start date:
May 15, 2021
Estimated Completion Date:
October 31, 2024
Connect with a study center
Zhongnan Hospital of Wuhan University
Wuhan, Hubei 430071
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.